TY - JOUR
T1 - IL-10 augments antibody production in in Vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation
AU - Xu, Qianghua
AU - Katakura, Yoshinori
AU - Yamashita, Makiko
AU - Fang, Shengguo
AU - Tamura, Takashi
AU - Matsumoto, Shin Ei
AU - Aiba, Yoshihiro
AU - Teruya, Kiichiro
AU - Osada, Kazuhiro
AU - Nishikawa, Ryuhei
AU - Shirahata, Sanetaka
PY - 2004/11
Y1 - 2004/11
N2 - An in vitro immunization (IVI) protocol enables antigen specific antibody production from L-Leucyl-L-Leucine methyl ester (LLME)-treated human peripheral blood lymphocytes (PBL) upon antigen stimulation in the presence of IL-2, IL-4, and muramyl dipeptide. In the course of our studies, we have found that IL-10 added at the antigen sensitization significantly augmented antibody production level from the LLME-treated PBL. In the present study, we tried to demonstrate the role of IL-10 in the augmentation of antibody production in an IVI protocol by clarifying the cytokine expression profiles in CD4+ and CD8 + T cells. The results showed that IL-10 skewed the Th1/Th2 balance to Th2-type responses by suppressing Th1-type cytokine production and augmenting Th2-type cytokine production in CD4+ and CD8+ T cells, as well as in CD19+ B cells. Furthermore, IL-10 augmented the expression of CD38, an antigen marker of plasma cells, on B cells, which clearly indicates that IL-10 promoted differentiation and maturation of B cells in an IVI protocol. These results indicate that IL-10 plays an important role in setting the cellular milieu to produce antibodies in an IVI protocol.
AB - An in vitro immunization (IVI) protocol enables antigen specific antibody production from L-Leucyl-L-Leucine methyl ester (LLME)-treated human peripheral blood lymphocytes (PBL) upon antigen stimulation in the presence of IL-2, IL-4, and muramyl dipeptide. In the course of our studies, we have found that IL-10 added at the antigen sensitization significantly augmented antibody production level from the LLME-treated PBL. In the present study, we tried to demonstrate the role of IL-10 in the augmentation of antibody production in an IVI protocol by clarifying the cytokine expression profiles in CD4+ and CD8 + T cells. The results showed that IL-10 skewed the Th1/Th2 balance to Th2-type responses by suppressing Th1-type cytokine production and augmenting Th2-type cytokine production in CD4+ and CD8+ T cells, as well as in CD19+ B cells. Furthermore, IL-10 augmented the expression of CD38, an antigen marker of plasma cells, on B cells, which clearly indicates that IL-10 promoted differentiation and maturation of B cells in an IVI protocol. These results indicate that IL-10 plays an important role in setting the cellular milieu to produce antibodies in an IVI protocol.
UR - http://www.scopus.com/inward/record.url?scp=19944379794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944379794&partnerID=8YFLogxK
U2 - 10.1271/bbb.68.2279
DO - 10.1271/bbb.68.2279
M3 - Article
C2 - 15564665
AN - SCOPUS:19944379794
VL - 68
SP - 2279
EP - 2284
JO - Bioscience, Biotechnology and Biochemistry
JF - Bioscience, Biotechnology and Biochemistry
SN - 0916-8451
IS - 11
ER -